Validity of models for predicting BRCA1 and BRCA2 mutations
- PMID: 17909205
- PMCID: PMC2423214
- DOI: 10.7326/0003-4819-147-7-200710020-00002
Validity of models for predicting BRCA1 and BRCA2 mutations
Abstract
Background: Deleterious mutations of the BRCA1 and BRCA2 genes confer susceptibility to breast and ovarian cancer. At least 7 models for estimating the probabilities of having a mutation are used widely in clinical and scientific activities; however, the merits and limitations of these models are not fully understood.
Objective: To systematically quantify the accuracy of the following publicly available models to predict mutation carrier status: BRCAPRO, family history assessment tool, Finnish, Myriad, National Cancer Institute, University of Pennsylvania, and Yale University.
Design: Cross-sectional validation study, using model predictions and BRCA1 or BRCA2 mutation status of patients different from those used to develop the models.
Setting: Multicenter study across Cancer Genetics Network participating centers.
Patients: 3 population-based samples of participants in research studies and 8 samples from genetic counseling clinics.
Measurements: Discrimination between individuals testing positive for a mutation in BRCA1 or BRCA2 from those testing negative, as measured by the c-statistic, and sensitivity and specificity of model predictions.
Results: The 7 models differ in their predictions. The better-performing models have a c-statistic around 80%. BRCAPRO has the largest c-statistic overall and in all but 2 patient subgroups, although the margin over other models is narrow in many strata. Outside of high-risk populations, all models have high false-negative and false-positive rates across a range of probability thresholds used to refer for mutation testing.
Limitation: Three recently published models were not included.
Conclusions: All models identify women who probably carry a deleterious mutation of BRCA1 or BRCA2 with adequate discrimination to support individualized genetic counseling, although discrimination varies across models and populations.
Figures
Comment in
-
Cancer risk models: translating family history into clinical management.Ann Intern Med. 2007 Oct 2;147(7):515-7. doi: 10.7326/0003-4819-147-7-200710020-00009. Ann Intern Med. 2007. PMID: 17909212 No abstract available.
Summary for patients in
-
Summaries for patients. Validity of models for predicting BRCA1 and BRCA2 mutations.Ann Intern Med. 2007 Oct 2;147(7):I38. doi: 10.7326/0003-4819-147-7-200710020-00001. Ann Intern Med. 2007. PMID: 17909202 No abstract available.
References
-
- Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401–1408. PMID: 9145676. - PubMed
-
- Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–1130. PMID: 12677558. - PMC - PubMed
-
- King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–646. PMID: 14576434. - PubMed
-
- Newman B, Millikan RC, King MC. Genetic epidemiology of breast and ovarian cancers. Epidemiol Rev. 1997;19:69–79. PMID: 9360904. - PubMed
Publication types
MeSH terms
Grants and funding
- P50 CA088843/CA/NCI NIH HHS/United States
- RC4 CA153828/CA/NCI NIH HHS/United States
- P50CA62924-05/CA/NCI NIH HHS/United States
- CA78284/CA/NCI NIH HHS/United States
- R01 CA 36397/CA/NCI NIH HHS/United States
- R01 CA 63705/CA/NCI NIH HHS/United States
- M01 RR00043/RR/NCRR NIH HHS/United States
- P30 CA051008/CA/NCI NIH HHS/United States
- P30-CA-51008/CA/NCI NIH HHS/United States
- 5P30 CA06973-39/CA/NCI NIH HHS/United States
- K05 CA-90754/CA/NCI NIH HHS/United States
- P50 CA062924/CA/NCI NIH HHS/United States
- P30 CA006973/CA/NCI NIH HHS/United States
- U01 CA078284/CA/NCI NIH HHS/United States
- K05 CA090754/CA/NCI NIH HHS/United States
- P50CA88843/CA/NCI NIH HHS/United States
- R01CA105090-01A1/CA/NCI NIH HHS/United States
- M01 RR000043/RR/NCRR NIH HHS/United States
- R01 CA105090/CA/NCI NIH HHS/United States
- HL 99-024/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous